Dana-farber-cancer Institute Inc.

Harvard College

Christopher Sweeney

Philip W Kantoff

Gwo-Shu Mary Lee

Kazumasa Komura

Svitlana Tyekucheva

Lorelei Mucci

Curtis Huttenhower

Travis Gerke

Gwo-sho Mary Lee

Daniela Bornigen

Xiaodong Wang

Kristina Jordahl

The present invention provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on using KDM5D expression level to identify which patients with hormone sensitive prostate cancer benefit from primary castration and taxane and who with castration resistant prostate cancer would benefit from docetaxel plus an androgen receptor antagonists added to the ongoing castration. The disclosure also provides methods of screening for and diagnosing prostate cancer and methods of choosing a therapeutic for prostate cancer based on a lower KDM5D expression having a more aggressive clinical course of prostate cancer in human patients.

Compositions and methods for screening and diagnosis of prostate cancer

The present invention provides methods for screening and diagnosing prostate cancer based on a correlation between cancer cell growth, cancer lethality or recurrence and the expression level of ZFP36 or NEDD9 and PTEN in conjunction with ZFP36. The disclosure also provides methods for screening and diagnosing prostate cancer based on a correlation between cancer lethality and the genotype of rs1910301 SNP. Also provided are methods for treating prostate cancer comprising providing a treatment or monitoring based on the expression level of ZFP36, the expression level of NEDD9, and the expression level of ZFP36 in conjunction with PTEN levels or the genotype of rs1910301 SNP.

Compositions and methods for screening and identifying clinically aggressive prostate cancer

Growing community of inventors

Waban, MA, United States of America

Christopher Sweeney